Lilly, with new data, to seek FDA approval of obesity drug retatrutide

Eli Lilly announced successful Phase 3 trial data for retatrutide, its triple-agonist obesity drug, and plans to file for FDA approval in Q1 2027. The drug showed 21-23% body weight loss in patients with diabetes or cardiovascular disease, positioning Lilly as a potential first-mover in the triple-G class.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.